Client Testimonials

“Our partnership with PathoQuest represents a significant step forward in our commitment to empower tomorrow’s therapies today. PathoQuest’s expertise in NGS technology will greatly enhance our capabilities and allow us to deliver even greater value to our clients through our comprehensive viral vector services, from process development to cGMP manufacturing for clinical and commercial supply.”

Robert Panting

General Manager

Rentschler Biopharma, ATMP

“We highly recommend PathoQuest as a trusted partner for next generation sequencing (NGS)-based viral safety testing. At Tr1X, we have collaborated with PathoQuest to support the development of our allogeneic, off-the-shelf, regulatory T cell therapies for the treatment of autoimmune diseases. Due to the complexity of our cell therapies and the use of donor pooling in select programs, ensuring the absence of adventitious agents in the final drug product is critical. PathoQuest’s NGS platform has played a key role in enabling us to consistently meet regulatory standards while maintaining a rapid and reliable batch release timeline. Their expertise and dependable testing services have been essential to our ability to deliver safe, high-quality therapies.”

James Adams

Chief Technical Officer

Tr1X

“IAVI has chosen to work with PathoQuest as the iDTECT Virome approach has permitted us to adopt next generation sequencing (NGS) for viral safety testing, replacing the traditional in vivo and in vitro testing for the release of our vaccine vectors in a safe and timely manner. We also appreciate their virology expertise in trouble-shooting and problem-solving for safety testing of our viral vectors.”

Eddy Sayeed

Executive Director, Process Development & Vaccine Manufacturing

IAVI

"PathoQuest's NGS testing services have been instrumental in reaching the milestone of clinical trial authorization. Their precise and reliable data contributes to the success of our trials."

Miriam Bazan-Peregrino

V.P., Translational Development

Theolytics

"We have been impressed by PathoQuest’s excellent service. They supported us with their NGS-based Quality Control platform, enabling us to navigate technical and regulatory hurdles to reach a key milestone. PathoQuest has been a reliable and trustworthy partner for biosafety testing."

Jack Elands, PhD

Former Chief Executive Officer

Emergence Therapeutics AG (recently acquired by Eli Lilly)

"We chose PathoQuest NGS viral safety tests for rapid and reliable Quality Control of our therapeutic cancer vaccine in development, ensuring batch release in weeks instead of months"

Christophe Ancel, PharmD

V.P. Pharmaceutical Operations & Qualified Person

Transgene SA

"PathoQuest's implementation of Next-Generation Sequencing (NGS) solutions has enhanced our approach to viral safety testing. It enabled us to streamline analyses, delivering comprehensive results within four weeks. This collaboration has been instrumental in strengthening the quality control of our advanced therapies, ensuring compliance and confidence."

Pauline Souêtre

ATMPs Quality Control Manager

Etablissement Français du Sang (CDMO)

"Our collaboration with PathoQuest is helping our customers overcoming the limitations of traditional QC methods. As a CDMO, using PathoQuest's NGS assays, we can advance our customers projects safely, while ensuring timelines are met."

Nicolas Salavin

Head of Transformation & Integration

OXB (CDMO)